News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Lumenis Ltd. (LUME) Introduces SCAAR FX(TM)



4/20/2012 9:30:56 AM

YOKNEAM, Israel, April 19, 2012 /PRNewswire/ -- Lumenis Ltd., the world's largest medical laser company, introduces SCAAR FX (Synergistic Coagulation and Ablation for Advanced Resurfacing), a noted advancement in CO(2) laser treatment capability.

At the American Society for Laser Medicine and Surgery's (ASLMS) annual meeting (April 18-22, 2012) in Kissimmee, Florida, Lumenis will unveil UltraPulse's unique SCAAR FX mode. SCAAR FX enables the treatment of surgical and acne scars, commonly characterized as conspicuous, complex and deep skin lesions, which require synergistic coagulation and ablation for advanced resurfacing. Initial treatments with SCAAR FX have shown remarkable results and minimal side effects. Using precision and high energy impact (up to 150 mJ per pulse per spot), SCAAR FX allows direct impact up to four millimeters deep into the skin tissue, four times deeper than other CO(2) lasers.

According to Dr. Matteo Tretti Clementoni, plastic surgeon at the Department of Dermatological Surgery and Laser Institute Europeo, Milan, Italy, "Hypertrophic scars consist of contracted tissue of varying thicknesses. With SCAAR FX, I am able to treat deep skin conditions, like hypertrophic scars, with the results of enhanced skin condition and improved quality of life for patients with these types of deep lesions. UltraPulse's SCAAR FX has the unique combination of short pulse durations and high energy per pulse which enables deep, precise and effective treatment."

Using a unique ablation/coagulation ratio, UltraPulse with SCAAR FX was designed to substantially improve structure of deep contracted skin lesions, such as surgical scars. This leads to increased range of motion in these areas and enhanced skin appearance. Other CO(2) lasers on the market only reach a depth of approximately one millimeter per pulse, and are limited by less than optimum ablation/coagulation ratios, which may lead to unsatisfactory results.

"The module expansion of UltraPulse with the new SCAAR FX technology is an exciting advancement for Lumenis. We're thrilled to provide a mode which may enable physicians to offer a significantly better quality of life for patients with deep skin lesions requiring advanced modality, such as conspicuous scars," said Dov Ofer, CEO of Lumenis.

Lumenis will be presenting SCAAR FX at booth #508 at ASLMS.

About Lumenis

Lumenis, the world's largest medical laser company, is a global developer, manufacturer and distributor of laser and light-based devices for surgical, aesthetic and ophthalmic applications, with more than 900 employees worldwide. Lumenis has 265 registered patents, over 260 FDA clearances, an installed base of over 80,000 systems and a presence in over 80 countries. Lumenis endeavors to bring the finest state of the art technology products to the market, fulfilling the highest standards of excellence, quality and reliability, delivering premium value and service to its customers. The name Lumenis is derived from the Latin words meaning "Light of Life" highlighting the light - the basis of our technologies - used to enhance life. For more information about Lumenis and its products, please visit: www.lumenis.com.

For further information contact:

Michelle Maydan
Director of Corporate Communications
1-866-569-0597
+972-4-959-9004
e-mail: mmaydan@lumenis.com

Lumenis® is a registered trademark of Lumenis and its affiliated companies.

UltraPulse® is a registered trademark of Lumenis Ltd.

SCAAR FX is a trademark of Lumenis Ltd.

SOURCE Lumenis


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES